51 unknown, 38 recruiting, 28 not yet recruiting, 25 completed. 107 Phase 2, 30 Phase 1, 16 Phase 3, 6 Not applicable, 4 Phase 4.
Follow HMPL-013: new trials by email Literature Review of HMPL-013 trials Research Report on HMPL-013
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer Fruquintinib, Sintilimab, Irinotecan Hydrochloride Liposome Injection (II) - Stomach Neoplasms, Gastric Cancer | Phase 2 | Not yet recruiting | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 20 | 2026-10-01 | 2026-09-14 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma LBL-024 for Injection, Bevacizumab injection, Oxaliplatin injection - Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 369 | 2026-09-28 | 2026-10-16 |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan BL-M07D1, Regorafenib, Fruquintinib - Colorectal Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 130 | 2026-08-01 | 2026-08-27 |
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer IBI363 + bevacizumab, Investigator's choice of therapy - Colorectal Cancer | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 550 | 2026-07-31 | 2026-08-10 |
| Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Sacituzumab Tirumotecan + Fruquintinib - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 45 | 2026-07-31 | 2026-07-09 |
| A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer HDM2017, Fruquintinib - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 120 | 2026-07-15 | 2026-06-02 |
| Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma fruquintinib + sintilimab + SOX, Sinitilimab+SOX - Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Sichuan University | 120 | 2026-06-15 | 2026-06-22 |
| Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer Oral Paclitaxel Solution Plus Fruquintinib, Investigator Choice (IC) Chemotherapy - Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Not applicable | Recruiting | Harbin Medical University | 150 | 2026-06-10 | 2026-08-17 |
| A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer Iparomlimab and Tuvonralimab (QL1706), Fruquintinib, Heterogeneous Radiotherapy - Metastatic Colorectal Cancer (CRC), mCRC | Phase 2 | Not yet recruiting | Huazhong University of Science and Technology | 60 | 2026-05-01 | 2026-03-30 |
| Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K) Fruquintinib - Colon Cancer | Phase 2 | Not yet recruiting | Korea University Anam Hospital | 88 | 2026-05-01 | 2026-04-06 |
| A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer S-531011, Fruquintinib, Pembrolizumab - Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Center Hospital East | 68 | 2026-05-01 | 2026-05-18 |
| SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study SHR-3821 and fruquintinib - Colorectal Cancer | Phase 2 | Not yet recruiting | Meng Qiu | 12 | 2026-04-27 | 2026-04-07 |
| Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer Fruquintinib - Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological | Not applicable | Recruiting | Federation Francophone de Cancerologie Digestive | 300 | 2026-03-10 | 2026-05-26 |
| FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) - Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS) | Phase 4 | Not yet recruiting | Ye Xu | 42 | 2026-03-01 | 2026-03-03 |
| A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets - HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 142 | 2026-03-01 | 2026-03-19 |
| JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan JSKN003, Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. - HER2-positive Colorectal Cancer | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 123 | 2026-02-06 | 2026-02-03 |
| Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer Fruquintinib Combined With Chemotherapy - Metastatic Colorectal Cancer (CRC) | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 50 | 2026-01-27 | 2026-04-09 |
| Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART), Standard Third-Line Therapy - Colorectal Cancer | Phase 2 | Not yet recruiting | Tao Zhang | 76 | 2026-01-21 | 2026-01-20 |
| A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. DSP107 + Atezolizumab, Fruquintinib - Colorectal Cancer | Phase 2 | Recruiting | Kahr Bio Australia Pty Ltd | 90 | 2026-01-16 | 2026-08-20 |
| Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC Fruquintinib plus Cetuximab-beta - Metastatic Colorectal Cancer (CRC) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 46 | 2026-01-16 | 2026-07-24 |
Showing 20 of 155. Sign in to see all of them.
Colorectal Neoplasms (69) · Stomach Neoplasms (16) · Colonic Neoplasms (10) · Rectal Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (3) · Neoplasms (3) · Sarcoma (3) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1)
Fudan University (14) · Hutchison Medipharma Limited (14) · Sun Yat-sen University (9) · Hutchmed (8) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · Federation Francophone de Cancerologie Digestive (3) · Henan Cancer Hospital (3) · Huazhong University of Science and Technology (3) · Liu Huang (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Chinese Academy of Medical Sciences (2) · Chinese PLA General Hospital (2) · Dai, Guanghai (2) · Fujian Medical University (2)
China (114) · United States (20) · France (5) · Australia (3) · Germany (3) · South Korea (3) · Austria (2) · Italy (2) · Japan (2) · Poland (2) · Belgium (1) · Czechia (1) · Estonia (1) · Hungary (1) · Malaysia (1)
Weijian Guo (2) · William Schelman, MD, PhD (2) · Youngiun Kim, MD (2) · Abdullah Esmail, MD (1) · Abi Vainstein-Haras (1) · Aiping Zhou, M.D. (1) · Alexander Stein, Prof. Dr. (1) · Arvind Dasari, MD (1) · Bin Xiong, doctor (1) · Dawei Li, PhD (1) · Dingwei Ye (1) · Fei Ma, M.D. (1) · Feng Wang (1) · Guanghai Dai, Doctor (1)
PMID 29946728, PMID 28103904, PMID 20516446, PMID 22767582, PMID 23642329, PMID 27299749, PMID 28596308, PMID 29528793, PMID 30348638, PMID 30357594, PMID 31272709, PMID 31481761, PMID 31999946, PMID 32499235, PMID 32901330, PMID 33325251, PMID 33993740, PMID 34408440, PMID 36628898, PMID 37130518, PMID 37133585, PMID 37331369, PMID 37796398, PMID 37842200, PMID 38341203, PMID 39395266, PMID 39755582, PMID 39806128, PMID 39945972, PMID 39952149, PMID 40022044, PMID 40077903, PMID 40163688, PMID 40485075, PMID 40888992, PMID 41005780, PMID 41246975, PMID 41423492, PMID 42206059, PMID 42871678, PMID 9006748
2025 (2), 2019 (1), 2023 (1)